PARADIGM BIOPHARMACEUTICALS LIMITED (PAR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PAR - PARADIGM BIOPHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.01
Index: ALL-ORDS

Paradigm Biopharmaceuticals is an Australian biotech company focused on the repurposing of the drug Pentosan Polysulphate Sodium for treatment of conditions sustained by inflammation. It has been listed since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.25

08 May
2024

-0.005

OPEN

$0.25

-1.96%

HIGH

$0.27

278,210

LOW

$0.25

TARGET
$0.47

-0.93 change from previous day

 88.0% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
PAR: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx N/A - 20.1 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-17.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx18.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-45.2 M
Net Profit Margin xxxxxxxxxxxxxxx-111,013.71 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-108.16 %
Return on Invested Capital xxxxxxxxxxxxxxx-107.37 %
Return on Assets xxxxxxxxxxxxxxx-88.16 %
Return on Equity xxxxxxxxxxxxxxx-108.16 %
Return on Total Capital xxxxxxxxxxxxxxx-122.16 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx56 M
Price To Book Value xxxxxxxxxxxxxxx5.20

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx-
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx59 M
Research & Development xxxxxxxxxxxxxxx53 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

09/05/2024

1

Speculative Buy

$0.47

88.00%

Paradigm Biopharmaceuticals is expecting FDA feedback from its recent discussions on the pathway for iPPS which could prove to be a positive in the short term for the company, notes Bell Potter.

The discusssions centred around the design of the phase 3 and confirmatory study for treatment of osteoarthritis with iPPS. The analyst notes that doses lower than the 2mg twice weekly for 6 weeks have proven ineffective in pain treatment. 

Patient results have shown up no toxity or safety concerns, inferring the FDA will approve the minimum dose.

Bell Potter adjusts earnings and the valuation for expected equity raisings from shareholders over FY25/FY26 to fund the two Phase 3 trials.

A Speculative Buy rating is retained and the target drops to 47c from $1.40.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -20.10 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -6.20 cents.
Access Stockbroker Research History >

PAR STOCK CHART

FNArena News on PAR

1
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023 - Small Caps
2
Research To Download: Amaero, Bell Financial, Pointerra, Wrkr, and others

Oct 23 2023 - FYI
3
Research To Download: Pharma & Biotech, Pointerra, Rent.com.au, & More

Aug 09 2023 - FYI
4
Research To Download: Cannindah, Comms, Hot Chili, Kinatico & Lithium Power

Jul 12 2023 - FYI
5
Research To Download: Kinatico, Qantm, State Gas & Vection Technologies

Jun 15 2023 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps
2
The Power Of New Weight-Loss Drugs

Apr 03 2024 - International
3
Dr Boreham’s Crucible: Neuren Pharmaceuticals

Mar 11 2024 - Small Caps
4
Spotlight On ASX-Listed Cannabis Companies

Jan 31 2024 - Small Caps
5
Transformational Trial Results For Neuren Pharmaceuticals

Dec 20 2023 - Small Caps
6
Dr Boreham’s Crucible: Imugene

Dec 11 2023 - Small Caps
7
Dr Boreham’s Crucible: PYC Therapeutics

Nov 22 2023 - Small Caps
8
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023 - Small Caps
9
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
10
Dr Boreham’s Crucible: Cleo Diagnostics

Aug 30 2023 - Small Caps